Monday June 26, 7:02 am Eastern Time
Company Press Release
SOURCE: InterMune Pharmaceuticals, Inc.
InterMune Acquires Rights to ACTIMMUNE(R) in
Canada
BURLINGAME, Calif., June 26 /PRNewswire/ -- InterMune Pharmaceuticals, Inc. (Nasdaq: ITMN - news) announced
today that it has acquired from Genentech, Inc. (NYSE: DNA - news) the exclusive rights for ACTIMMUNE© in Canada for
a broad range of indications including: chronic granulomatous disease (CGD), osteopetrosis, idiopathic pulmonary fibrosis and
infectious diseases. The license will require InterMune to pay royalites to Genentech on all sales in Canada.
``Access to the Canadian market, which is approximately 10% the size of the U.S. market, will allow us to leverage our existing
development and commercialization infrastructure. Furthermore, Canadian physicians have experience using ACTIMMUNE©
to treat CGD and osteopetrosis, and we are working with several clinicians in Canada for our Phase III trial in idiopathic
pulmonary fibrosis,'' stated W. Scott Harkonen, M.D., President and Chief Executive Officer of InterMune.
InterMune Pharmaceuticals, Inc. is a biotechnology company dedicated to the development and commercialization of
innovative products for the treatment of serious pulmonary, infectious and congenital diseases. InterMune currently markets
ACTIMMUNE© (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease
(CGD) and osteopetrosis. For more information about InterMune and ACTIMMUNE©, please visit InterMune's web sites at
intermune.com and actimmune.com, or send e-mail to ir@intermune.com.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human
pharmaceuticals for significant unmet medical needs. Thirteen of the approved products of biotechnology stem from Genentech
science. Genentech markets eight products directly in the United States. The company has headquarters in South San
Francisco, California, and is traded on the New York Stock Exchange under the symbol DNA.
Except for the historical information contained herein, this press release contains certain forward-looking statements that involve
risks and uncertainties. All forward-looking statements and other information included in this press release are based on
information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such
forward-looking statements or information. InterMune's actual results could differ materially from those described in
InterMune's forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited
to, those discussed under the heading ``Risk Factors'' and the risks and factors discussed in InterMune's Registration Statement
on Form S-1 declared effective on March 23, 2000 by the Securities and Exchange Commission (File No. 333-96029) and
InterMune's most recent 10-Q filed with the SEC. In sum, these significant risks include, but are not limited to, the success of
InterMune's efforts in research, development, commercialization, product acceptance, third-party manufacturing and capital
raising; product liability lawsuits; uncertainties associated with: obtaining and enforcing patents important to its business, being
an early-stage company and relying on third-party payors' reimbursement policies; the lengthy and expensive regulatory process
and competition from other products. Even if InterMune's products appear promising at an early stage of development, they
may not reach the market for a number of reasons. Such reasons include, but are not limited to, the possibilities that the
potential products will be found ineffective during clinical trials, fail to receive the necessary regulatory approvals, be difficult to
manufacture on a large scale, be uneconomical to market or be precluded from commercialization by the proprietary rights of
third parties.
SOURCE: InterMune Pharmaceuticals, Inc. |
